Assessing ‘No Evidence of Disease Activity’ Status in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study

CNS Drugs - United Kingdom

doi 10.1007/s40263-017-0482-4